Path to market: PRR has a path to market – it can follow Dendreon (DNDN US, not rated) which is in the US market with Provenge, an immunotherapy prostate cancer
recurrence vaccine. As a fast follower, we believe PRR’s manufacturing technology has the potential to BETTER THAN DNDN’s."
From the Nomura Report.
- Forums
- ASX - By Stock
- IMM
- dndn q3 result
IMM
immutep limited
Add to My Watchlist
0.00%
!
24.0¢

dndn q3 result, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $350.4M |
Open | High | Low | Value | Volume |
24.5¢ | 24.5¢ | 24.0¢ | $129.2K | 531.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 150003 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 40000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1297 | 0.250 |
1 | 7412 | 0.245 |
10 | 254373 | 0.240 |
6 | 406782 | 0.235 |
12 | 307151 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 11672 | 3 |
0.245 | 180000 | 2 |
0.250 | 154580 | 5 |
0.255 | 72009 | 4 |
0.260 | 215703 | 7 |
Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
RAC
RACE ONCOLOGY LTD
Dr Pete Smith, Executive Chairman
Dr Pete Smith
Executive Chairman
SPONSORED BY The Market Online